Why It Matters

Becton, Dickinson and Co. is a longstanding, heavily invested player in Washington lobbying, employing a hybrid strategy on Medicare coverage, supply chains and cybersecurity.

For Q3 2025, BD maintained its core in-house lobbying operation at $550,000 in expenditures, supplemented by specialized external firms like Tarplin, Downs & Young LLC on Medicare reimbursement and TRADEWINS LLC on trade policy.

BD’s lobbying directly affects several imminent policy outcomes:

By the Numbers

Becton, Dickinson and Co. spent $550,000 on in-house lobbying during Q3 2025, conducting advocacy directly through its own employees rather than external firms.

The company has maintained a continuous lobbying presence since 2003, filing 276 disclosures and spending approximately $34.7 million historically. BD’s lobbying priorities have centered on health issues (78 mentions), taxation and internal revenue code (62 mentions), budget and appropriations (60 mentions), Medicare and Medicaid (53 mentions), and trade policy (34 mentions). While this quarter’s filing was handled in-house, the Q3 2025 disclosure did not provide details on specific internal lobbyists involved in the filing.

The Agenda

Becton, Dickinson and Co. is lobbying on several interconnected healthcare policy issues including:

  • Medicare Coverage Pathways: Multiple bills advancing through Congress—including H.R. 5343 and H.R. 4441—would accelerate coverage for breakthrough devices, directly impacting BD’s market access timelines and reimbursement rates for its portfolio.
  • Supply Chain & Tariffs: The Medical Supply Chain Resiliency Act could reshape tariff structures on medical goods, affecting BD’s manufacturing costs and global supply chain strategy.
  • Cybersecurity & Domestic Manufacturing: Congressional focus on vulnerabilities in Chinese-made devices creates both regulatory obligations and competitive advantages for domestically-manufactured alternatives, where BD maintains significant operations.
  • Regulatory Modernization: Pending legislation on electronic labeling and device accessibility standards would reshape compliance requirements across BD’s product lines.

    Broader Context

Congress is actively reshaping the policy landscape for medical devices across multiple fronts that directly impact BD’s business. The 119th Congress has demonstrated bipartisan momentum on accelerating Medicare coverage for breakthrough devices—a longstanding industry priority—with H.R. 5343 passing the House Ways and Means Committee 38-3 in September 2025. Simultaneously, cybersecurity vulnerabilities in Chinese-made medical devices are driving congressional focus on strengthening domestic manufacturing and supply chain resilience, creating momentum for trade and tariff reform through the bipartisan Medical Supply Chain Resiliency Act.

Lawmakers are also modernizing FDA regulations through bills like the Medical Device Electronic Labeling Act and advancing Medicare payment pathways for emerging technologies like AI-enabled devices. These legislative priorities align closely with BD’s stated lobbying agenda on breakthrough device coverage, supply chain strengthening, FDA modernization, and healthcare cybersecurity—suggesting the company is positioned to benefit from legislative momentum on core business issues.

Between The Lines

Congress is actively advancing legislation and holding oversight hearings directly aligned with BD’s lobbying priorities. The House Ways and Means Committee passed H.R. 5343, the Ensuring Patient Access to Critical Breakthrough Products Act, on a strong 38-3 vote, creating expedited Medicare coverage pathways for FDA-designated breakthrough devices. Simultaneously, H.R. 4441, the Patient Access to Innovative New Technologies Act, advances similar goals with bipartisan backing from Reps. Blake Moore (R-UT) and Lori Trahan (D-MA). The bipartisan Medical Supply Chain Resiliency Act (H.R. 2213/S.998) seeks to eliminate tariffs on medical goods and diversify supply sources. On cybersecurity, lawmakers held a hearing titled Aging Technology, Emerging Threats: Examining Cybersecurity Vulnerabilities in Legacy Medical Devices that examined vulnerabilities in older devices still widely used in hospitals.

The Medical Device Electronic Labeling Act (H.R. 1539) and Medical Device Nonvisual Accessibility Act (H.R. 5605) reflect regulatory modernization efforts. Additionally, Sen. Heinrich and Sen. Rounds introduced the Health Tech Investment Act to establish Medicare payment pathways for AI-enabled medical devices. Members have been vocal supporters: Reps. Moore, Bilirakis, and Trahan, along with Sens. Padilla and Young, issued statements promoting breakthrough device access, while Rep. Schakowsky reintroduced her accessibility legislation.

Competitive Landscape

Becton, Dickinson and Co. is lobbying alongside other major medical device manufacturers and industry trade associations on overlapping healthcare and supply chain priorities. Medline Industries Inc. similarly lobbies on device sterilization, supply chain resilience, and tariff issues. The Advanced Medical Technology Association (AdvaMed), the sector’s leading trade association, coordinates broader industry advocacy on FDA regulation, Medicare reimbursement, AI regulation, and R&D tax credits. Other competitors include the Medical Device Manufacturers Association and AdvaMed Imaging, which focus on device approval processes, sterilization, cybersecurity, and specialized reimbursement issues. This collective industry effort demonstrates coordinated advocacy around FDA processes, Medicare access for breakthrough devices, supply chain strengthening, and tariff policies.

The Bottom Line

Becton, Dickinson and Co. is maintaining consistent advocacy across medical device policy as Congress actively debates legislation aligned with the company’s priorities. The 119th Congress is advancing bipartisan bills on Medicare coverage acceleration, supply chain resilience, and cybersecurity standards—all core BD lobbying areas.

Still, the company faces headwinds including FDA approval slowdowns and evolving cybersecurity regulatory requirements. BD’s $550,000 quarterly spend reflects a standard advocacy investment for a major medical device manufacturer operating in an active legislative environment where outcomes remain uncertain.